Filing Details

Accession Number:
0000914190-19-000519
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-23 16:31:34
Reporting Period:
2019-12-20
Accepted Time:
2019-12-23 16:31:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
842023 Bio-Techne Corp TECH Biological Products, (No Disgnostic Substances) (2836) 411427402
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1534980 R. Charles Kummeth 614 Mckinley Place Ne
Minneapolis MN 55413
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-12-20 5,767 $67.46 135,756 No 4 M Direct
Common Stock Disposition 2019-12-20 5,767 $222.06 129,989 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2019-12-20 5,767 $0.00 5,767 $67.46
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
39,348 2020-04-01 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 100 Indirect By Step-Son
Common Stock 100 Indirect By Step-Daughter
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Options (Right to Buy) $86.25 2021-04-01 46,316 46,316 Direct
Common Stock Stock Options (Right to Buy) $94.35 2021-08-12 66,849 66,849 Direct
Common Stock Stock Options (Right to Buy) $108.49 2022-08-07 95,346 95,346 Direct
Common Stock Stock Options (Right to Buy) $108.49 2022-08-07 79,517 79,517 Direct
Common Stock Stock Options (Right to Buy) $106.59 2023-08-18 154,169 154,169 Direct
Common Stock Stock Options (Right to Buy) $106.59 2023-08-18 102,779 102,779 Direct
Common Stock Restricted Stock Units $0.00 21,291 21,291 Direct
Common Stock Stock Options (Right to Buy) $125.05 2024-08-09 117,342 117,342 Direct
Common Stock Stock Options (Right to Buy) $125.05 2024-08-09 78,228 78,228 Direct
Common Stock Restricted Stock Units $0.00 16,918 16,918 Direct
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 90,334 90,334 Direct
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 60,222 60,222 Direct
Common Stock Restricted Stock Units $0.00 16,937 16,937 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 85,725 85,725 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 57,150 57,150 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2021-04-01 46,316 46,316 Direct
2021-08-12 66,849 66,849 Direct
2022-08-07 95,346 95,346 Direct
2022-08-07 79,517 79,517 Direct
2023-08-18 154,169 154,169 Direct
2023-08-18 102,779 102,779 Direct
21,291 21,291 Direct
2024-08-09 117,342 117,342 Direct
2024-08-09 78,228 78,228 Direct
16,918 16,918 Direct
2025-08-08 90,334 90,334 Direct
2025-08-08 60,222 60,222 Direct
16,937 16,937 Direct
2026-08-07 85,725 85,725 Direct
2026-08-07 57,150 57,150 Direct
Footnotes
  1. Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. Fully exercisable.
  5. Options to purchase 25,695 shares vest on each of 8/18/2017, 8/18/2018 and 8/18/2019 and options to purchase 25,695 shares vest on 8/18/2020.
  6. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  7. Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  8. Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
  9. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  10. Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022.
  11. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  12. Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.